Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients

被引:0
|
作者
Michalowska-Wender, G
Losy, J
Wender, M
机构
[1] Polish Acad Sci, Neuroimmunol Unit, Med Res Ctr, PL-60355 Poznan, Poland
[2] Med Univ, Dept Neuroimmunol, Poznan, Poland
来源
FOLIA NEUROPATHOLOGICA | 2001年 / 39卷 / 01期
关键词
multiple sclerosis; immunological markers; cytokines; cerebrospinal fluid;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In patients suspected of multiple sclerosis (MS), even in the case of MRI positive changes, cerebrospinal fluid (CSF) analysis is of great practical value. Until now, however, only IgG index, restricted oligoclonal IgG bands and the examination of IgG subclasses have been of practical value. The determination of other immunological markers is too expensive to be introduced into laboratory diagnostic standards in MS. However, the clinical trials should be monitored by a large set of markers of MS activity, including the estimation of anti MBP antibodies, presence of MBP material in the CSF and concentration of sVCAM-1, ICAM-1, PECAM-1 in CSF and serum.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 50 条
  • [31] Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis
    Hein , Katharina
    Koehler, Anushka
    Diem, Ricarda
    Saettler, Muriel B.
    Demmer, Iris
    Lange, Peter
    Baehr, Mathias
    Otto, Markus
    NEUROSCIENCE LETTERS, 2008, 436 (01) : 72 - 76
  • [32] Intrathecal B cell-related markers for an optimized biological investigation of multiple sclerosis patients
    Feki, Sawsan
    Damak, Mariem
    Sakka, Salma
    Ben Ali, Yesmine
    Mejdoub, Sabrina
    Bouattour, Nadia
    Hachicha, Hend
    Mhiri, Chokri
    Masmoudi, Hatem
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [33] Intrathecal B cell-related markers for an optimized biological investigation of multiple sclerosis patients
    Sawsan Feki
    Mariem Damak
    Salma Sakka
    Yesmine Ben Ali
    Sabrina Mejdoub
    Nadia Bouattour
    Hend Hachicha
    Chokri Mhiri
    Hatem Masmoudi
    Scientific Reports, 12
  • [34] Biological monitoring of IFN-β therapy in Multiple Sclerosis
    Bertolotto, A.
    Granieri, L.
    Marnetto, F.
    Valentino, P.
    Sala, A.
    Capobianco, M.
    Malucchi, S.
    Di Sapio, A.
    Malentacchi, M.
    Matta, M.
    Caldano, M.
    CYTOKINE & GROWTH FACTOR REVIEWS, 2015, 26 (02) : 241 - 248
  • [35] Extracellular vesicles as molecular biomarkers to monitor response to Multiple Sclerosis therapy
    Torres Iglesias, Gabriel
    Lopez Molina, MariPaz
    Chamorro, Beatriz
    Fernandez-Fournier, Mireya
    Puertas Munoz, Inmaculada
    Alonso Lopez, Elisa
    Diez Tejedor, Exuperio
    Gutierrez-Fernandez, Maria
    Otero, Laura
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 350 - 350
  • [36] Dubious therapy for patients with multiple sclerosis
    Goldenberg, G
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (05): : 694 - 695
  • [37] Electroconvulsive therapy in patients with multiple sclerosis
    Rasmussen, Keith G.
    Keegan, B. Mark
    JOURNAL OF ECT, 2007, 23 (03) : 179 - 180
  • [38] Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report
    So Yamada
    Shoko Merrit Yamada
    Hiroshi Nakaguchi
    Mineko Murakami
    Katsumi Hoya
    Akira Matsuno
    Kazuto Yamazaki
    Yasuo Ishida
    Journal of Medical Case Reports, 6 (1)
  • [39] Retrovirus MSRV and gliotoxic factor: potential biological markers in multiple sclerosis
    Perron, H
    ANNALES DE BIOLOGIE CLINIQUE, 1998, 56 (04) : 427 - 438
  • [40] Matrix metalloproteinases in multiple sclerosis - Targets of therapy or markers of injury?
    Bever, CT
    Rosenberg, GA
    NEUROLOGY, 1999, 53 (07) : 1380 - 1381